J&J has been hunting for companies to buy. At the start of the year, the company’s new CEO Joaquin Duato said J&J would take a more “aggressive” approach to dealmaking, although he and other executives had indicated a preference toward small- and mid-sized acquisitions of medical technology and biotechnology companies.
Analysts had previously speculated that J&J could acquire a cardiology firm such as Boston Scientific.
In a statement, Duato said in the acquisition of Abiomed is “an important step in the execution of our strategic priorities” as the company focuses on its pharma and medtech businesses.
“We have committed to enhancing our position in medtech by entering high-growth segments,” he added. “The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.” READ MORE
by Elise Reuter
Source: biopharmadive.com
Roquette (Lestrem, France) announced the successful completion of its acquisition of IFF Pharma Solutions from International Flavors & Fragrances Inc. (IFF; New York City). This strategic milestone marks a significant step forward in its ambition to become a leader in support of the global pharma markets.
Merck KGaA, Darmstadt, Germany and SpringWorks Therapeutics, Inc. (Stamford, Conn.), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced the companies have entered into a definitive agreement for Merck KGaA to acquire SpringWorks Therapeutics.
“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to licensure—a radical departure from past practices,” the Department of Health and Human Services (HHS) said in a statement to CNN.
